Jerry Isaacson
Recent Quotes
"RNN's Archexin could generate $175M-$524M in peak annual revenues."
—
Jerry Isaacson, LifeSci Capital
(5/23/16)
more >
"IMUC will initiate a Phase 3 trial of ICT-107 based on the results of Phase 2."
—
Jerry Isaacson, LifeSci Capital
(4/2/15)
more >
"New results help define the potential for THLD's Phase 3 success."
—
Jerry Isaacson, LifeSci Advisors
(1/27/15)
more >
"DMPI's refractory GBM drug also has immediate opportunities in front-line GBM, a $1B opportunity."
—
Jerry Isaacson, LifeSci Advisors
(1/9/15)
more >
"Initial data from THLD's TH-302 with TBorD trial are encouraging."
—
Jerry Isaacson, LifeSci Advisors
(12/12/14)
more >
"THLD's partner Merck completed MAESTRO enrollment ahead of schedule."
—
Jerry Isaacson, LifeSci Advisors
(11/7/14)
more >
"We are initiating coverage on THLD."
—
Jerry Isaacson, LifeSci Advisors
(9/15/14)
more >
"DMPI announced FDA approval for an expanded dosing regimen in a Phase 1/2 trial evaluating VAL-083 in glioblastoma multiforme patients."
—
Jerry Isaacson, LifeSci Advisors
(8/21/14)
more >
